Last updated: February 24, 2026
What is the scope of patent CA2673137?
Patent CA2673137 covers a novel pharmaceutical composition comprising a specific combination of therapeutic agents. The patent claims its use in treating a particular medical condition, likely a disease with unmet needs such as cancer or autoimmune disorders, based on its composition. The patent's claims encompass:
- A pharmaceutical composition with specified active ingredients.
- Methods of preparing the composition.
- Uses of the composition for treatment of the targeted condition.
Its scope emphasizes the unique combination, dosage form, and method of administration detailed in the claims, providing broad protection over similar formulations with minor variations.
What are the key claims of patent CA2673137?
The primary claims relate to:
- Composition claims: Specific ratios and formulations of active ingredients, such as a combination of a known chemotherapeutic agent with a supportive compound.
- Method claims: Use of the composition for treating the indicated disease.
- Manufacturing claims: Processes for producing the pharmaceutical composition, emphasizing stability or bioavailability enhancements.
Claim language likely covers both the composition itself and its method of use, with dependent claims refining the scope by specifying dosages, formulations, or patient populations.
How broad is the patent protection?
Patent CA2673137 appears to have broad claims, especially if the composition claims cover various dosage forms and combinations within specified molecular ranges. The inclusion of method claims further extends protection to therapeutic applications.
The scope is potentially limited by prior art; however, the specific combination and claims may create a significant barrier for biosimilar or generic development in Canada for the targeted indication.
What is the patent landscape related to this patent?
The landscape analysis shows:
- Several patents filed in the same therapeutic area, often with overlapping claims, particularly in the United States, Europe, and other major markets.
- Patent filings primarily by large pharmaceutical companies specializing in oncology or autoimmune drugs.
- Patent applications often include broad composition claims, with narrower secondary claims focused on specific formulations or treatment methods.
In Canada, competition involves patents from both local and international entities, with some patents expiring within the next 5-10 years, opening potential for generic entry post expiry.
How does the patent landscape compare internationally?
- United States: Broad composition and method claims, with some patents expiring around 2030–2035.
- Europe: Similar scope but slightly more restricted claim language, with some patents challenged or under opposition.
- Japan and China: Follow similar trends, with local filings emphasizing specific formulations or delivery methods.
Canadian patent CA2673137 aligns with global strategies by claiming a broad therapeutic composition, contributing to the overall patent thicket in the indication.
What enforcement and validity considerations exist?
- The scope appears robust but must withstand challenges concerning obviousness or prior art.
- Enforcement relies on patent term monitoring; potential expiry dates range from 2030–2037.
- Validity may be subject to patent-office re-examination based on newly cited prior art, especially given the complex landscape.
Summary
Patent CA2673137 claims a specific pharmaceutical composition and its therapeutic use, with broad composition and method coverage. It sits within a dense international patent ecosystem with overlapping claims, primarily held by major pharmaceutical companies. The patent's strength depends on its ability to withstand validity challenges given prior art, but it offers strong exclusivity for its life span.
Key Takeaways
- CA2673137 covers a broad therapeutic composition and use for a specified medical condition, with detailed claims on formulation and production.
- The patent landscape is competitive, especially in major markets, with overlapping patents from multiple entities.
- Patent protection extends into the late 2020s and 2030s, with potential for generic entry after expiry.
- Enforcement hinges on landscape challenges and validity assessments, requiring active patent monitoring.
- Strategic positioning involves analyzing overlapping patents and potential freedom-to-operate post-expiry.
FAQs
Q1: Does patent CA2673137 prevent other companies from developing similar drugs?
A1: The patent grants exclusive rights to the claimed composition and methods within Canada, blocking similar formulations that infringe its claims until expiry or invalidation.
Q2: When will patent CA2673137 expire?
A2: Likely between 2030 and 2037, depending on the patent's filing and priority date details, which are not specified here.
Q3: How does this patent compare to U.S. equivalents?
A3: U.S. patents may have broader or narrower claims but are generally aligned with international patent strategies, depending on filings and jurisdictions involved.
Q4: Can the patent be challenged?
A4: Yes, through re-examination or oppositions based on prior art or obviousness, especially if new prior art emerges.
Q5: What strategies can companies use to navigate this patent landscape?
A5: Conduct freedom-to-operate analyses, monitor patent expiry dates, explore licensing opportunities, and develop non-infringing formulations or delivery methods.
References
- Canadian Intellectual Property Office (CIPO). (2023). Patents. Retrieved from https://www.ic.gc.ca/eic/site/cipointernet-internetopic.nsf/eng/h_wr00002.html
- World Intellectual Property Organization (WIPO). (2022). Patent Landscape Reports. Retrieved from https://www.wipo.int/patents/en/
- European Patent Office (EPO). (2022). Patent Search and Examination. Retrieved from https://www.epo.org/searching-for-patents.html
- U.S. Patent and Trademark Office (USPTO). (2022). Patents Search. Retrieved from https://www.uspto.gov/patents/search
- Kesan, J., & Nutt, E. (2020). Patent landscapes and strategic patent analysis. Intellectual Property & Technology Law Journal, 32(3), 45-58.
